Acute liver injury has been associated with the death of two non-ambulatory DMD patients treated with Elevidys.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA ...

Sarepta Therapeutics, Inc. (SRPT) on Tuesday said that the U.S. Food and Drug Administration (FDA) has approved dosing in a study cohort to evaluate the use of an immunosuppressive regimen as part of ...

The financing exercise at Sarepta Therapeutics continues as uncertainty remains for the company’s flagship gene therapy Elevidys. The Massachusetts biopharma has reached an agreement with some ...

SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- On July 24, 2025, the European Medicines Agency (“EMA”) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta’s medication ...

Sarepta Therapeutics Inc. shares rose sharply Tuesday after US regulators reversed course and recommended that patients who can walk be allowed to take its gene therapy Elevidys again. The Food and ...

Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its rating from Equal Weight to Underweight and lowered its price target for the ...

Sarepta Therapeutics, Inc. SRPT reported second-quarter 2025 adjusted EPS of $2.02, which beat the Zacks Consensus Estimate of $1.11. This beat was mainly due to higher-than-expected collaboration ...